The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...

Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...

FDA halts actions on makers of compounded drugs as it reviews decision to remove Eli Lilly's (LLY) weight loss drug ...

Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, from its ...

We recently compiled a list of the 10 Most Promising Growth Stocks According to Hedge Funds. In this article, we are going to ...

If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Rival manufacturers fight for the right to sell weight loss drugsThere’s a new fight brewing between ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

Weight-loss medications like the popular versions made by Denmark's Novo Nordisk A/S (CSE:NOVOb) and US peer Eli Lilly ...

As the demand for weight loss injectables soars, so too does the market for off-brand alternatives, some of which may not be safe or effective.

This lengthy study with the drug Mounjaro seems to point to even better success than they’d hoped. Eli Lilly, the mind behind ...